Pfizer's Paxlovid reduces COVID risk in seniors regardless of vaccine status -study

Pfizer's Paxlovid reduces COVID risk in seniors regardless of vaccine status -study Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus. Ari Rabinovitch Reuters

...

Use of Pfizer's pills, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared in the United States along with a spike infections. Biden administration officials have pushed for wide use of Paxlovid, which the government purchased and provides free.

Pfizer's clinical trial tested Paxlovid in unvaccinated people who had risk factors for serious disease and found that the two-drug treatment cut the risk of hospitalization and death by 90%. That was during the Delta wave of the virus...